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Comparison of guanadrel and guanethidine 
Hoth guanadrel and guanethidine caused a statistically significant reduction of blood pressure 
when compared to placebo, but there was no significant difference between the 2 drugs, 
regarding antihypertensive potency. With guanadrel it was possible to achieve significantly 
more control of the blood pressure throughout the day. There also were fewer complaints of 
early morning dizziness during the guanadrel period, and there was less diarrhea. The effects 
of both drugs on cardiac output and total peripheral vascular resistance were identical in the 
resting recumbent position and during tilting. 
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For many years guanethidine (Ismelin) 
has been a widely us cd drug for the control 
of severe hypertension, Its hypotensive ef-
fect stems from moderate reduction of 
cardiae outputS- ll in combination with de-
creased peripheral vascular resistance." 1:' 
Both effects are the result of catecholamine 
depletion in the adrenergic nerve endings 
in the myocardium and the blood vessel 
walls. Some of the side effects of guan-
ethidine are disturbing, e.g., its tendency to 
cause carly morning hypotensionG• Hand 
diarrhea, In addition, the slow onset of ac-
tion and the sustained effect following with-
drawal!;·!J often make fine adjustments of 
blood pressure control difficult in patients. 
For these reasons, there has long been a 
need for a drug with the potency of guan-
ethidine but without some of its undesirable 
effects. 
Received for publication Aug. 3, 1972. 
Accepted for publication Sept. 8, 1972. 
204 
Guanadrel, which was introduced re-
cently, is an adrenergic blocking agent with 
hypotensive action. It is similar to guan-
ethidine in many ways and acts by causing 
a peripheral catecholamine depletion. 7 
However, its effect is conSiderably shorter 
than that of guanethidine, being in the 
order of 6 to 8 hours." Thus, it would seem 
possible to achieve a more balanced control 
of blood pressure throughout the day. As 
initial results with guanadrel seemed to 
suggest complete absence of diarrhea and 
less morning hypotension than with guan-
ethidine,' the present study was under-
taken. Our main interest has been to study 
the hemodynamie effects of oral treatment 
with guanadrel and to compare the blood 
pressure control and side effects of guan-
adrel and guanethidine. 
Materials and methods 
Twenty-one patients with moderately 
severe hypertension took part in the study: 
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Table I. Means and standard errors of blood lJ1'es8ure on guanadl'el, guanethidine, 
and placebo 
Morning Afternoon 
Recumbent 
I 
Standing Recumbent I Standing 
S I D S I D S I D I s I D 
Guanadrel 
Placebo 
Difference 
152.8 ± 5.0 105.2 ± 6.1 
172.7 ± 8.0 116.0 ± 3.9 
139.3 ± 4.8 lOLl ± 3.0 156.8 ± 4.3 100.7 ± 3.0 141.9 ± 3.6 97.7 ± 2.9 
171.8 ± 8.6 121.7 ± 4.0 175.0 ± 7.8 114.7 ± 4.4 171.7 ± 8.7 118.7 ± 4.1 
20.1 10.8 32.5 20.6 18.2 14.0 29.8 21.0 
p value 0.05 0.0005 0.005 0.0005 0.05 0.01 0.0005 0.0005 
Guanethidine 
Placebo 
Differencp 
152.8 ± 5.4 99.6 ± 1.9 137.6 ± 7.1 
165.8 ± 4.2 113.3 ± 2.9 164.6 ± 4.9 
94.7 ± 4.8 159.7 ± 4.1 105.6 ± 3.1 
119.5 ± 3.4 168.4 ± 4.3 111.9 ± 3.6 
146.8 ± 4.4 100.5 ± 3.6 
164.5 ± 5.2 116.4 ± 3.5 
13.0 13.7 27.0 
p value 0.02 0.0002 0.002 
(Cuanadrel-
guanethidine) 
Difference 0 
p value ns 
5.6 
ns 
l.7 
ns 
19 males and 2 females whose average age 
was 41 years (range 17 to 68). Only pa-
tients in whom diuretic trcatment alone 
had failed to control the blood pressure 
were selected. All were without overt heart 
failure (less than Grade Il, New York 
Heart Association classification), severe 
kidney failure (creatinine clearance over 
40 m!. per minute), or Grades III and IV 
hypertensive retinopathy (Keith-Wagener-
Barker) . Twenty patients had essential 
hypertension, as determined after complete 
laboratory work-up including: serum elec-
trolytes, urinary ketosteroids, catechol-
amines, and aldosteronc, as well as normal 
hypertensive urograms. One patient had 
chronic pyelonephritis with sccondary 
hypertension. 
Eight patients were chosen for evalua-
tion of the hemodynamic effect of both 
drugs. These patients were studied in the 
early phase whcn initial experience was 
needed in an open label design. The aim 
of the treatment was to achieve best practi-
cal blood pressure control with increasing 
doses of both compounds. Best practical 
control was defined as normal blood pres-
sure or lowest possible reading without 
causing intractablc side effects after a 
minimum of 6 or maximum of 12 weeks of 
treatment. At the end of each period, intra-
24.8 8.7 6.3 17.7 15.9 
0.0005 ns ns 0.005 0.01 
6.4 
ns 
-2.9 
ns 
-4.9 
0.02 
-4.9 2.8 
artcrial blood pressures were measured and 
cardiac outputs were determined by dye 
dilution technique. The method has been 
described in detail previously.':! 
Thirtecn patients were chosen for a 
single-blind crossover study to compare 
the effect of both drugs on home blood 
pressure rccorded by patients who were 
unaware of the treatment regimen. Side 
effects were evaluated by a "blind" ob-
server who used a standardized question-
naire. Patients were receiving chlorothia-
zide, 50 mg. 2 times daily, and the "active" 
drug for 2 periods each 6 weeks in length. 
Between those 2 periods there was a 2 
week period of placebo when the only 
active treatment was chlorothiazide. Two 
of the authors (L. Hansson and A. Pascual) 
were in touch with patients and adjusting 
the "active drug" to achieve the best practi-
cal blood pressure control. Randomization 
was assured by predetermined closed enve-
lopes so that patients started with either 
guanadrel or guanethidine. Six patients were 
started with guanadrel, while 7 received 
guanethidine during the first period of ac-
tive treatment. The average daily dosage of 
guanadrel was 70 mg. (25 to 150) and of 
guanethidine, 57 mg. (25 to 125). Guan-
ethidine was administered once daily while 
guanadrel was used in 3 divided doses. 
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Table 11. Differences between guanadrel and guanethidine regarding morning to 
afternoon alterations of blood pressure 
A.M. to' P.M. differences 
Systolic recumbent Diastalic recumbent Systolic standing Diastolic standing 
blood pressure blaod pressure blood pressure bload pressure 
Guanadrel 
Guanethidine 
.3.1 
6.1 
-4.7 
6,2 
1.6 
9,3 
-0.2 
9,5 
Difference 
p value 
3.0 ± 2.5 10.9 ± 4.4 7.7 ± 4.5 9.7 ± 3.6 
< 0.05 ns < 
Table Ill. Side effects mentioned by 
patients 
Guan-
Side effects ethidine 
Dizziness on arising 2 3 7 
Dizziness during 
the day .3 4 5 
Headaches 5 7 7 
Dreams 5 6 6 
Insomnia 4 1 4 
Tiredness 7 7 9 
Shortness of breath ,'3 .3 5 
Nasal blocking ,'3 :1 5 
Cold extremities 1 4 
Dry mouth 6 7 5 
Unpleasant taste 3 5 -I 
Sore tongue 
Pain in angle of jaw 2 2 1 
Diarrhea .3 2 6 
Constipation 1 1 1 
Nocturia 6 4 6 
Failure of ejaculation 10 8 10 
Poor erection 4 3 4 
Conjunctivitis 1 2 
Blurred vision 1 1 
The student t test for paired observations 
has been used in all statistical comparisons. 
When comparing the effect on the blood 
pressure, the average home blood pressure 
recordings during the last 7 days of guan-
adrel, guanethidine, and placebo treatment. 
respectively, have been used. 
Results 
Randomized study. 
Blood pressure control. As can be seen 
in Table I, both guanadrel and guanethi-
dine caused a significant reduction of blood 
pressure. There was no significant differ-
0.05 ns 
ence in antihypertensive potency of the 
active drugs. In the afternoon, both re-
cumbent and standing diastolic blood pres-
sures increased Significantly more during 
treatment with guanethidine (Table 11). 
This, however, was not the case with sys-
tolic blood pressure. 
Side effects. Both drugs caused a number 
of side effects (Table Ill). Complaints of 
failure of ejaculation were made by 10 
patients after both drugs. Only 2 patients 
complained of early morning dizziness dur-
ing guanadrel treatment as compared to 
7 after guanethidine. Diarrhea occurred in 
3 patients during the guanadrel period and 
in 6 while taking guanethidine. The total 
number of complaints during guanadrel 
treatment was 70, 93 during guanethidine, 
and 67 during "placebo" therapy. 
Hemodynamic effects. There was no sig-
nificant difference between the effects of 
guanethidine and guanadrel on heart rate, 
intra-arterial blood pressure, cardiac index, 
and total peripheral vascular resistance 
either in the recumbent or tilted position 
(Table IV). Both drugs caused a marked 
reduction of cardiac output during tilt, 
with a substantial drop of systolic blood 
pressure and a moderate increase of total 
peripheral resistance. 
Discussion 
In a randomized single-blind cross-over 
study, both guanadrel and guanethidine 
decreased blood pressure to the same ex-
tent, probably by similar hemodynamic 
mechanisms since no significant differences 
of cardiac output or total peripheral re-
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Table IV. Comparative hemodynamic effects of guanethidine and guanadrel 
Qi 
56.7 166.1 90.2 22.74 2.84 63.8 139.6 86.8 26.98 2.10 
Guanethidine ± 6.5 ± 24.5 I- 15.2 ± 8.38 ± 0.62 ± 8.3 ± 25.1 ± 20.8 ± 8.10 ± 0.04 
59.6 153.6 84.2 2l.51 2.74 65.7 134.1 82.1 27.53 2.02 
Cuanadrel ± 6.3 + 19.8 + 5.9 ± 0.05 ± 0.61 ± 14.2 + 13.6 + 10.8 ± 9.67 ± 0.43 
Significance ns ns ns ns ns ns ns ns ns ns 
Hemodynamic response to guanethidine and guanadrel resting recumbent and after 5 minutes of 45° head-up tilt. HR = 
heart rate (beats/min.); BAs = brachial artery systolic blood pressure (mm. Hg.); BAd = brachial artery diastolic blood 
pressure; = tota penphera resJstance ; 1 = car me In ex ltel'S mm. 0 y sur ace area . TPR I · I' (Mean blood pressure) Q' d" d (I' /. /b d f ) 
Cardiac output 
sistance were detected. However, the usu-
ally observed rise in blood pressure 
throughout the day during guanethidine 
therapy was not seen after guanadrel. Con-
sequently, morning to afternoon changes 
of recumbent and standing diastolic blood 
pressure were larger with guanethidine 
(p < 0.05). This difference may be at-
tributed to the shorter duration of the 
guanadrel effect, which necessitates ad-
ministration 3 times daily, but in turn gives 
a more stable control of the blood pres-
sure. On the other hand, it has been shown 
that the early morning hypotension of 
guanethidine treatment persists even if the 
drug is administered 3 times daily.G 
The complaints of dizziness upon rising 
were also more frequent during the guan-
ethidine period and thus further support 
the impression that guanadrel offers a more 
even control of blood pressure. 
Another important side effect of guan-
ethidine treatment is diarrhea; again, 
guanadrel caused fewer complaints. This 
may be attributed to the fact that guana-
drel depletion of intestinal catecholamine 
stores is less than quanethidine depletion.10 
Other side effects such as failure of 
ejaculation seem to be equally frequent. 
The surprisingly high frequency of this 
complaint during the intervening placebo 
period is of interest, but may be attribut-
able to the short duration of placebo. 
In summary, the following conclusions 
can be drawn: (1) The hypotensive ef-
fective and other hemodynamic effects of 
guanadrel are comparable to those of 
guanethidine. (2) Guanadrel provides a 
more stable control of the blood pressure 
characterized bv a more even reduction 
of diastolic blood pressure throughout the 
day. (3) Diarrhea is less frequent during 
treatment with guanadrel. 
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